Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EpiDestiny

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

- PMLiVE

Novo Nordisk: Tresiba makes a solid start

Long-acting insulin capturing share of diabetes market

- PMLiVE

Novo Nordisk chooses Mexico to launch urban diabetes plan

‘Cities Changing Diabetes’ partnership programme launches in Mexico City before global roll out

- PMLiVE

Novo Nordisk will build $100m facility in Denmark

Bagsvaerd site will support growing diabetes pipeline

- PMLiVE

Trial boost for Novo’s IDegLira ambitions

Company says drug shows weight benefits and low risk of hypoglycaemia

- PMLiVE

Novo Nordisk names SVP biopharmaceuticals in US

Promotion for Eddie Williams

- PMLiVE

Novo partners with NHS on diabetes care

Danish pharma company will work with King’s Health Partners in South London

Biogen Idec building

Biogen Idec taps Sangamo for blood disorder drugs

Deal is worth up to $320m

- PMLiVE

US approval for Novo’s Factor XIII drug Tretten

Becomes first recombinant treatment licensed for a rare clotting disorder

- PMLiVE

Police to probe Novo Nordisk over disclosure delay

Regulator says pharma company was late to announce FDA decision to not approve Tresiba and Ryzodeg

- PMLiVE

Study highlights poor diabetes consultation

Less than a third of patients asked for input into their treatment plans

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links